CD19 Protein (AA 20-291) (Fc Tag,Biotin)

Catalog No. ABIN2180717

This Recombinant CD19 protein is expressed in HEK-293 Cells and has been mentioned in 2+ publications.

Quick Overview for CD19 Protein (AA 20-291) (Fc Tag,Biotin) (ABIN2180717)

Target: CD19 (CD19 Molecule (CD19))

Protein Type: Recombinant

Biological Activity: Active

Origin: Human

Source: HEK-293 Cells

Purity: >95 % as determined by reduced SDS-PAGE.

Product Details

Protein Characteristics: AA 20-291

Purification tag / Conjugate: This CD19 protein is labelled with Fc Tag,Biotin.

Brand: MABSol®,UltraLys

Sequence: AA 20-291

Specificity: The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with biotins using standard chemical labeling method. A standard biotin reagent (13.5 angstroms) is used in this product.

Characteristics: This protein carries a human IgG1 Fc fragment at the C-terminus. The protein has a calculated MW of 56.3 kDa. The protein migrates as 56-66 kDa on a SDS-PAGE gel under reducing (R) condition due to glycosylation.

Sterility: 0.22 μm filtered

Endotoxin Level: Less than 1.0 EU per μg by the LAL method.

Application Details

Comment:

A chemically labeled biotinylated protein with ultra sensitivity.
The product is produced using a chemical labeling approach. The primary amines in the side chains of lysine residues and the N-terminus of protein are conjugated with biotins.
Chemical labeling usually results in multiple biotin attachment on a single protein molecule, which could potentially lead to higher detection sensitivity.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: PBS, pH 7.4

Handling Advice: Please avoid repeated freeze-thaw cycles.

Storage: -20 °C

Storage Comment: No activity loss was observed after storage at: In lyophilized state for 1 year (4 °C), After reconstitution under sterile conditions for 3 months (-70 °C).

References

Chen, Zhou, Zhang, Wang, Hu, Wang, Wang: "TREM1/Dap12-based CAR-T cells show potent antitumor activity." in: Immunotherapy, Vol. 11, Issue 12, pp. 1043-1055, (2019) (PubMed).

MacLeod, Antony, Martin, Moser, Hekele, Wetzel, Brown, Triggiano, Hux, Pham, Bartsevich, Turner, Lape, Kirkland, Beard, Smith, Hirsch, Nicholson, Jantz, McCreedy: "Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells." in: Molecular therapy : the journal of the American Society of Gene Therapy, Vol. 25, Issue 4, pp. 949-961, (2017) (PubMed).

Target Details

Target: CD19 (CD19 Molecule (CD19))

Alternative Name: CD19

Background: B-lymphocyte antigen CD19, is a single-pass type I membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains. CD19 is expressed on follicular dendritic cells and B cells. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. As on T cells, several surface molecules form the antigen receptor and form a complex on B lymphocytes. The (almost) B cell-specific CD19 phosphoglycoprotein is one of these molecules. The others are CD21 and CD81. These surface immunoglobulin (sIg)-associated molecules facilitate signal transduction. On living B cells, anti-immunoglobulin antibody mimicking exogenous antigen causes CD19 to bind to sIg and internalize with it. The reverse process has not been demonstrated, suggesting that formation of this receptor complex is antigen-induced. This molecular association has been confirmed by chemical studies. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 has been shown to interact with: CD81, CD82, Complement receptor 2, and VAV2.

Molecular Weight: 56.3 kDa

NCBI Accession: NP_001761

Pathways: Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway